BDTX Black Diamond Therapeutics, Inc.
XNAS
1.62
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
BDTX
$1.62
—
What changed
Recent filings, trades and moves- Nov 10 Reported earnings after close
- Nov 10 Quarterly report (10-Q) filed
Key stats
$1.62
- 52-Week Range
- $1.58 – $4.94
- YTD
- -34.91%
- Straddle Price
- $1.25
- P/C Vol Ratio
- 0.20
- Market Cap
- $0.1B
- Open
- $1.68
- Day Range
- $1.62 – $1.69
- Volume
- 77,639
- Prev Close
- $1.59
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.84% |
| Beta vs SPY | 2.00 |
| Cost of Equity (CAPM) | 15.84% (VRP-adj) |
| WACC | 15.97% |
| Volatility Risk Premium | +168.6pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -44.3% |
| Book / Price | 90.1% — banking bias active (P/B is primary) |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $1.90 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $1.82 |
| Bollinger Width / SMA20 | 27.9% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: AMGN, BIIB, EXEL, GILD, HALO, KYMR, MRNA, NBIX, RVMD, TECH
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$13.93
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 27.5× · 6 peers |
| Peer EV/EBITDA | n/a | 0% | median 17.0× · 7 peers |
| Peer P/B | $20.33 | 65% | median 12.1× · 10 peers |
| Peer P/S | n/a | 0% | median 6.9× · 10 peers |
| Market Anchor (SMA50) | $1.90 | 35% | stability 10% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-11-10 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.1B
- Employees
- 21
- List Date
- 2020-01-30
- CIK
- 0001701541
- Last Earnings
- Nov 10 after close
- Headquarters
- Cambridge, MA
- Homepage
- https://www.blackdiamondtherapeutics.com
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) …
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -23.19% | -25.67% | 63.04% | 31.96% | 22.43% | 0.00% | 11.43% |
| Feb | 15.70% | -27.65% | -40.80% | 20.77% | -17.96% | -2.76% | -8.78% |
| Mar | -13.14% | -8.88% | 0.00% | 6.07% | -18.85% | -12.35% | -7.86% |
| Apr | 4.59% | -11.64% | -25.91% | 12.98% | 14.09% | 13.73% | 1.31% |
| May | -50.45% | -28.39% | 16.98% | -18.98% | 29.41% | -14.62% | -11.01% |
| Jun | -3.33% | 45.56% | 134.88% | -1.48% | 4.64% | -18.14% | 27.02% |
| Jul | -23.03% | 33.59% | -20.47% | 29.57% | 7.26% | -10.34% | 2.76% |
| Aug | 6.77% | -7.27% | -8.92% | 0.66% | 6.18% | 21.04% | 3.08% |
| Sep | -18.50% | -46.01% | -19.38% | -24.61% | 35.36% | -7.60% | -13.46% |
| Oct | -9.67% | 35.88% | -32.37% | -34.29% | 4.03% | -5.32% | -6.96% |
| Nov | -24.43% | -10.21% | 26.83% | -8.30% | -3.29% | -8.86%* | -4.71% |
| Dec | -9.51% | -12.62% | 19.07% | -17.37% | -35.54% | -- | -11.19% |
| Total | -84.00% | -67.82% | 17.19% | -25.37% | 25.89% | -41.38% | -29.25% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $1.81
SMA 50: $1.88
SMA 200: $2.16
Current: $1.62
EMA 12: $1.75
EMA 26: $1.80
MACD: -0.0514 | Signal: -0.0164
BEARISH
ADX (14): 14.68
RANGE
+DI: 18.89
−DI: 26.47
Momentum Oscillators
RSI (14): 42.38
NEUTRAL
Stoch %K: 18.74
Stoch %D: 20.90
Williams %R: -90.64
Volume & Volatility
BB Upper: $2.09
BB Lower: $1.54
NEUTRAL
OBV: 131,001,680
Vol SMA 20: 845,084
Vol ROC: -92.56%
ATR: $0.15
True Range: $0.09
HV 20: 115.7%
HV 30: 98.3%
HV 60: 76.2%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-12T00:00:00 – 2026-11-10T00:00:00
AI Analysis
Written before BDTX’s Nov 10 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report
System Prompt: Provide a comprehensive stock analysis report for BDTX, incorporating technical indicators, options metrics, beta analysis, market data, and recent news headlines.
Executive Summary: Overall assessment: BEARISH (Confidence level: 6/10) Key drivers and primary risks: * Bearish momentum signals from MACD and RSI * High volatility and implied volatility premium * Recent negative earnings report and mixed market sentiment Recent news sentiment impact: * Positive news headlines have had a limited impact, as bearish technical signals prevail
Technical Analysis: Trend Direction: * Short-term (1-4 weeks): Bearish * Medium-term (1-3 months): Range-bound * Long-term (3-12 months): Uptrend
Support/Resistance Levels: * Lower Bollinger Band: $2.07 * Middle Line: $2.77 * Upper Bollinger Band: $3.48
Momentum Signals: * RSI interpretation: Neutral, overbought >70, oversold <30 * MACD signal: Bearish, -0.06 / Signal: -0.09 / Histogram: 0.03 (bullish) * Bollinger Bands position: Mean reversion
Volume Analysis: * Volume SMA 20: 2058586.45 * On-Balance Volume (OBV): 82053094.36 * Volume Rate of Change: 137.64%
News & Sentiment Analysis: Recent Headlines Summary: * Positive news headlines from recent earnings report and partnerships * Mixed market sentiment with bearish technical signals
Sentiment Assessment: * Neutral, as positive news is countered by bearish technical indicators
Catalyst Identification: * Upcoming earnings report (no specific date available) * Product launches and regulatory updates may impact volatility
Market Narrative: * Technical signals suggest a bearish trend, while recent news headlines have had a limited impact
Risk & Volatility Assessment: Beta Interpretation: * High risk relative to market (beta >1.5)
Volatility Regime: * Current vs historical volatility levels: High volatility - stock moves more than market
Options Market Signals: * IV rank: 39.8% (Medium) * Put/call ratio: 0.72 (Neutral sentiment) * Unusual activity: None notable
Downside Protection: * Support levels: Lower Bollinger Band ($2.07) and Middle Line ($2.77)
Market Context & Positioning: Sector Performance: * Relative strength vs sector/market: Neutral to bearish
Institutional Activity: * Volume patterns suggesting institutional interest: None notable
Correlation Analysis: * How stock moves relative to market (R-squared interpretation): Correlated with market
Relative Valuation: * Position within trading range: Bearish, as stock is near the lower end of its trading range
Key Levels & Action Items: Critical Price Levels: * Support/resistance levels from moving averages and technical patterns
Breakout/Breakdown Levels: * Technical levels that could trigger significant moves: Lower Bollinger Band ($2.07) and Middle Line ($2.77)
Time-Sensitive Catalysts: * Earnings report (no specific date available) * Product launches and regulatory updates may impact volatility
Risk Management: * Stop-loss levels: None specified * Position sizing considerations: None notable
Generated
News
All BDTX news →
Earnings History
16 of 16 under expected move
Avg Expected Move
44.84%
Avg Actual Move
5.89%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-03-25 | After-Close | 8.28% | 0.31% | 0.04x | Within |
| 2021-08-12 | After-Close | 7.73% | 4.33% | 0.56x | Within |
| 2021-11-08 | After-Close | 24.97% | 0.12% | 0.00x | Within |
| 2023-03-09 | After-Close | 72.41% | 6.90% | 0.10x | Within |
| 2023-05-09 | After-Close | 39.01% | 3.30% | 0.08x | Within |
| 2023-08-11 | After-Close | 60.06% | 1.20% | 0.02x | Within |
| 2024-03-12 | After-Close | 34.39% | 10.85% | 0.32x | Within |
| 2024-05-09 | After-Close | 18.22% | 9.48% | 0.52x | Within |
| 2024-08-06 | Pre-Market | 20.75% | 5.57% | 0.27x | Within |
| 2024-11-05 | After-Close | 40.77% | 1.23% | 0.03x | Within |
| 2025-05-12 | After-Close | 42.86% | 10.29% | 0.24x | Within |
| 2025-08-07 | After-Close | 19.74% | 5.26% | 0.27x | Within |
| 2025-12-03 | Pre-Market | 256.52% | 22.03% | 0.09x | Within |
| 2026-03-16 | After-Close | 30.82% | 1.83% | 0.06x | Within |
| 2026-05-07 | After-Close | 17.46% | 9.93% | 0.57x | Within |
| 2026-08-06 | After-Close | 23.44% | 1.56% | 0.07x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
BDTX Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $1.25
7-DTE Move: $8.00
Days to Exp: 37 (2026-12-18)
Options Flow · All expiries
Call Volume: 909
Put Volume: 180
P/C Volume: 0.198
BULLISH
Call OI: 2,696
Put OI: 386
P/C OI: 0.143
Total OI: 3,082
ATM Options Pricing
ATM Call: $0.75
ATM Put: $0.50
Call %: 46.3%
Put %: 30.9%
Chain Summary
Chain Volume: 1,089
Chain OI: 3,082
Last Updated: 11/11/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 27th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
27%
vs own history
GEX tilt
+0.05
OI-weighted, today
Vanna tilt
+0.15
δ-sensitivity to IV
Charm tilt
-0.09
δ-decay vs time
? What is this?
· 3 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$1.25Nov 11
Beta Analysis
Risk Metrics
Beta: 1.8646
Alpha: -83.78%
Correlation: 0.3073
R-Squared: 9.4%
Stock Volatility: 83.0%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own BDTX
2 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $3.6M | #1632 of 3138 | +19.4% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $0K | #4622 of 4729 | 0.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
BDTX Institutional Ownership (13F)
Filings for 2026-06-30 · 33 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 57,273,136 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
6 filers$1.43M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | TORONTO DOMINION BANK | $791.80K | 55.35% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $333.00K | 23.28% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $195.73K | 13.68% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $50.32K | 3.52% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $35.44K | 2.48% | 2026-09-30 |
| 6 | GROUP ONE TRADING LLC Custodian | $24.23K | 1.69% | 2026-06-30 |
3 filers$324.31K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $225.70K | 69.59% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $97.68K | 30.12% | 2026-06-30 |
| 3 | GROUP ONE TRADING LLC Custodian | $925 | 0.29% | 2026-06-30 |
BDTX Insider Trading (Form 4)
Latest: 2026-09-21Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-21 | Ali Behbahani | Director | Award (A) | +7,707 | $1.93 | $14.9K | EDGAR |
| 2026-09-21 | Prakash Raman | Director | Award (A) | +6,801 | $1.93 | $13.1K | EDGAR |
| 2026-06-29 | Shannon Campbell | Director | Grant (A) | +40,000 opt | — | EDGAR | |
| 2026-06-29 | Garry E Menzel | Director | Grant (A) | +40,000 opt | — | EDGAR | |
| 2026-06-29 | Kapil Dhingra | Director | Grant (A) | +40,000 opt | — | EDGAR | |
| 2026-06-29 | Ali Behbahani | Director | Grant (A) | +40,000 opt | — | EDGAR | |
| 2026-06-29 | Prakash Raman | Director | Grant (A) | +40,000 opt | — | EDGAR | |
| 2026-06-29 | Samarth Kulkarni | Director | Grant (A) | +40,000 opt | — | EDGAR | |
| 2026-06-22 | Prakash Raman | Director | Award (A) | +7,907 | $1.66 | $13.1K | EDGAR |
| 2026-06-22 | Ali Behbahani | Director | Award (A) | +8,961 | $1.66 | $14.9K | EDGAR |
| 2026-03-20 | Prakash Raman | Director | Award (A) | +6,105 | $2.15 | $13.1K | EDGAR |
| 2026-03-20 | Ali Behbahani | Director | Award (A) | +6,919 | $2.15 | $14.9K | EDGAR |
| 2026-01-23 | Mark A. Velleca | PRESIDENT & CEO | Grant (A) | +600,000 opt | — | EDGAR | |
| 2026-01-23 | Elizabeth Buck | CHIEF SCIENTIFIC OFFICER | Grant (A) | +250,000 opt | — | EDGAR | |
| 2026-01-23 | Erika Jones | SEE REMARKS | Grant (A) | +200,000 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
BDTX Insider Holdings
10 insiders · @ $1.62
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Ali Behbahani | Director | 4,558,993 | $7.40M | $20.20M | 30 | 2026-09-21 |
| 2 | BB BIOTECH AG | 10%+ Owner | 3,233,547 | $5.25M | $6.75M | 10 | 2025-03-20 |
| 3 | Elizabeth Buck | CHIEF SCIENTIFIC OFFICER | 170,192 | $276.4K | $0 | 5 | 2026-01-23 |
| 4 | Mark A. Velleca | PRESIDENT & CEO | 121,522 | $197.4K | $0 | 13 | 2026-01-23 |
| 5 | Erika Jones | SEE REMARKS | 85,150 | $138.3K | $0 | 5 | 2026-01-23 |
| 6 | Brent Hatzis-Schoch | SEE REMARKS | 83,400 | $135.4K | -$1.31M | 18 | 2026-01-23 |
| 7 | Sergey Yurasov | CHIEF MEDICAL OFFICER | 75,000 | $121.8K | $0 | 4 | 2026-01-23 |
| 8 | Prakash Raman | Director | 51,840 | $84.2K | $0 | 14 | 2026-09-21 |
| 9 | Garry E Menzel | Director | 51,825 | $84.2K | $0 | 8 | 2026-06-29 |
| 10 | Shannon Campbell | Director | 8,865 | $14.4K | $0 | 7 | 2026-06-29 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
BDTX Board & Officers
As of SEC filings through Sep 21, 2026Directors 7
- Ali Behbahani · since Jan 29, 2020
- Garry E Menzel · since Jan 29, 2020
- Samarth Kulkarni · since Jan 29, 2020
- Kapil Dhingra · since Jan 19, 2021
- Mark A. Velleca · since Aug 9, 2021
- Prakash Raman · since Apr 10, 2024
- Shannon Campbell · since Apr 10, 2024
Officers 5
- Mark A. Velleca · President & CEO · listed since Sep 2023
- Erika Jones · Officer Title: Senior Vice President, Finance and Corporate Controller · listed since Jan 2025
- Brent Hatzis-Schoch · Officer Title: Chief Operating Officer and General Counsel · listed since Feb 2022
- Elizabeth Buck · Chief Scientific Officer · since Sep 15, 2021
- Sergey Yurasov · Chief Medical Officer · since Jun 10, 2022
Changes in the last 10 years (61)
| Mar 20, 2025 | Biotech Growth N V reported in an SEC filing no longer being a 10% owner |
| Mar 20, 2025 | Bb Biotech Ag reported in an SEC filing no longer being a 10% owner |
| Jan 31, 2025 | Erika Jones listed as Officer Title: Senior Vice President, Finance and Corporate Controller (previously Officer Title: Vice President, Finance and Corporate Controller) in SEC filings |
| Apr 10, 2024 | The company announced the departure of Wendy L Dixon from the board in an SEC filing |
| Apr 10, 2024 | The company announced the departure of Alexander Mayweg from the board in an SEC filing |
| Apr 10, 2024 | Shannon Campbell became a director |
| Apr 10, 2024 | Prakash Raman became a director |
| Jan 17, 2024 | The company announced the departure of Rajeev M. Shah from the board in an SEC filing |
| Sep 18, 2023 | Mark A. Velleca first listed as President & CEO in an SEC filing |
| Jul 7, 2023 | Ra Capital Management, L.p. first on file as a director |
| Jul 7, 2023 | RA Capital Nexus Fund, L.P. first on file as a director |
| Jul 7, 2023 | RA Capital Healthcare Fund LP first on file as a director |
| Jul 7, 2023 | Peter Kolchinsky first on file as a director |
| Dec 13, 2022 | Robert Alexander Ingram left the board, per their own SEC filing |
| Jun 10, 2022 | Sergey Yurasov became Chief Medical Officer |
| Apr 11, 2022 | Biotech Growth N V became a 10% owner |
| Apr 11, 2022 | Bb Biotech Ag became a 10% owner |
| Apr 6, 2022 | Wendy L Dixon became a director |
| Apr 5, 2022 | The company announced the departure of Bradley J PhD Bolzon from the board in an SEC filing |
| Feb 17, 2022 | Brent Hatzis-Schoch listed as Officer Title: Chief Operating Officer and General Counsel (previously Chief Operating Officer and General Counsel) in SEC filings |
| Nov 18, 2021 | Fang Ni became Officer Title: Chief Business Officer and interim Chief Financial Officer |
| Nov 18, 2021 | Erika Jones became Officer Title: Vice President, Finance and Corporate Controller |
| Nov 16, 2021 | The company announced the departure of Thomas Leggett as Chief Financial Officer in an SEC filing |
| Sep 15, 2021 | Elizabeth Buck became Chief Scientific Officer |
| Aug 9, 2021 | Mark A. Velleca became a director |
| Jan 19, 2021 | Kapil Dhingra became a director |
| Oct 2, 2020 | David M. Epstein listed as Officer Title: President and Chief Executive Officer (previously President and Chief Executive Officer) in SEC filings |
| Sep 25, 2020 | Robert Alexander Ingram became a director |
| Sep 8, 2020 | Rachel Humphrey became Chief Medical Officer |
| Jul 29, 2020 | Bradley J PhD Bolzon first listed as a 10% owner in an SEC filing |
| Feb 5, 2020 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. reported in an SEC filing no longer being a 10% owner |
| Feb 5, 2020 | Ali Behbahani no longer listed as a 10% owner in SEC filings |
| Jan 29, 2020 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. became a 10% owner |
| Jan 29, 2020 | Versant Voyageurs I, L.P. became a 10% owner |
| Jan 29, 2020 | Versant Voyageurs I Parallel, L.P. became a 10% owner |
| Jan 29, 2020 | Versant Venture Capital VI, L.P. became a 10% owner |
| Jan 29, 2020 | Versant Vantage I, L.P. became a 10% owner |
| Jan 29, 2020 | Thomas Leggett became Chief Financial Officer |
| Jan 29, 2020 | Scott D Sandell became a 10% owner |
| Jan 29, 2020 | Samarth Kulkarni became a director |
| Jan 29, 2020 | Rajeev M. Shah became a director |
| Jan 29, 2020 | Peter W. Sonsini became a 10% owner |
| Jan 29, 2020 | Paul Edward Walker became a 10% owner |
| Jan 29, 2020 | New Enterprise Associates 16, L.P. became a 10% owner |
| Jan 29, 2020 | Nea 16 Gp, LLC became a 10% owner |
| Jan 29, 2020 | NEA Partners 16, L.P. became a 10% owner |
| Jan 29, 2020 | Mohamad Makhzoumi became a 10% owner |
| Jan 29, 2020 | Joshua Makower became a 10% owner |
| Jan 29, 2020 | Garry E Menzel became a director |
| Jan 29, 2020 | Forest Baskett became a 10% owner |
| Jan 29, 2020 | David M. Epstein became a director |
| Jan 29, 2020 | David M. Epstein became President and Chief Executive Officer |
| Jan 29, 2020 | David M Mott became a 10% owner |
| Jan 29, 2020 | Christopher D. Roberts became Chief Scientific Officer |
| Jan 29, 2020 | Carmen Chang became a 10% owner |
| Jan 29, 2020 | Brent Hatzis-Schoch became Chief Operating Officer and General Counsel |
| Jan 29, 2020 | Bradley J PhD Bolzon became a director |
| Jan 29, 2020 | Anthony A. Florence Jr. became a 10% owner |
| Jan 29, 2020 | Ali Behbahani became a director |
| Jan 29, 2020 | Ali Behbahani became a 10% owner |
| Jan 29, 2020 | Alexander Mayweg became a director |
Not reported recently (25)
- Versant Vantage I, L.P. · Last reported as a 10% owner in an SEC filing dated Aug 30, 2024
- Versant Voyageurs I, L.P. · Last reported as a 10% owner in an SEC filing dated Aug 30, 2024
- Versant Venture Capital VI, L.P. · Last reported as a 10% owner in an SEC filing dated Aug 30, 2024
- Versant Voyageurs I Parallel, L.P. · Last reported as a 10% owner in an SEC filing dated Aug 30, 2024
- Fang Ni · Last reported as Officer Title: Chief Business Officer and interim Chief Financial Officer in an SEC filing dated Feb 15, 2024
- Peter Kolchinsky · Last reported as a director in an SEC filing dated Jul 7, 2023
- Ra Capital Management, L.p. · Last reported as a director in an SEC filing dated Jul 7, 2023
- RA Capital Nexus Fund, L.P. · Last reported as a director in an SEC filing dated Jul 7, 2023
- RA Capital Healthcare Fund LP · Last reported as a director in an SEC filing dated Jul 7, 2023
- David M. Epstein · Last reported as a director in an SEC filing dated Jun 28, 2023
- Bradley J PhD Bolzon · Last reported as a 10% owner in an SEC filing dated Jun 22, 2021
- Christopher D. Roberts · Last reported as Chief Scientific Officer in an SEC filing dated May 5, 2021
- Rachel Humphrey · Last reported as Chief Medical Officer in an SEC filing dated Feb 19, 2021
- Scott D Sandell · Last reported as a 10% owner in an SEC filing dated Jan 29, 2020
- David M Mott · Last reported as a 10% owner in an SEC filing dated Jan 29, 2020
- Peter W. Sonsini · Last reported as a 10% owner in an SEC filing dated Jan 29, 2020
- Paul Edward Walker · Last reported as a 10% owner in an SEC filing dated Jan 29, 2020
- Joshua Makower · Last reported as a 10% owner in an SEC filing dated Jan 29, 2020
- Carmen Chang · Last reported as a 10% owner in an SEC filing dated Jan 29, 2020
- Mohamad Makhzoumi · Last reported as a 10% owner in an SEC filing dated Jan 29, 2020
- Anthony A. Florence Jr. · Last reported as a 10% owner in an SEC filing dated Jan 29, 2020
- Nea 16 Gp, LLC · Last reported as a 10% owner in an SEC filing dated Jan 29, 2020
- New Enterprise Associates 16, L.P. · Last reported as a 10% owner in an SEC filing dated Jan 29, 2020
- NEA Partners 16, L.P. · Last reported as a 10% owner in an SEC filing dated Jan 29, 2020
- Forest Baskett · Last reported as a 10% owner in an SEC filing dated Jan 29, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
BDTX Proposed Insider Sales (Form 144)
Latest: 2024-07-31
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2024-07-31 | David Epstein | Former Employer | 50,000 | $310.0K | 2024-07-31 | UBS Financial Services Inc | — | EDGAR |
| 2024-07-26 | David Epstein | Former Employee | 50,000 | $310.0K | 2024-07-26 | UBS Financial Services Inc | — | EDGAR |
| 2024-07-16 | David Epstein | Former Employer | 50,000 | $312.5K | 2024-07-16 | UBS Financial Services Inc | — | EDGAR |
| 2024-07-11 | David Epstein | Former Employer | 69,024 | $345.1K | 2024-07-11 | UBS Financial Services Inc | — | EDGAR |
| 2024-07-09 | David Esptein | Former Employee | 75,000 | $360.0K | 2024-07-09 | UBS Financial Services Inc | — | EDGAR |
| 2024-06-28 | David Epstein | Former Employer | 50,000 | $250.0K | 2024-06-28 | UBS Financial Services Inc | — | EDGAR |
| 2024-06-27 | David Epstein | Former Board Member | 40,353 | $189.7K | 2024-06-27 | UBS Financial Services Inc | — | EDGAR |
| 2024-06-26 | David Epstein | Former Board Member | 9,647 | $45.3K | 2024-06-26 | UBS Financial Services Inc | — | EDGAR |
| 2024-06-24 | David Epstein | Former Board Member | 6,011 | $30.2K | 2024-06-24 | UBS Financial Services Inc | — | EDGAR |
| 2024-06-21 | David Epstein | Former Board Member | 743 | $3.7K | 2024-06-21 | UBS Financial Services Inc | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-10
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
29 ETFs hold BDTX
25 shown · $12.66M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $2.9M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.00% | $2.1M | $77.9B | 2026-11-06 |
| 3 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.02% | $1.1M | $6.6B | 2026-11-06 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $963,706 | — | 2026-09-30 |
| 5 | DFSV Dimensional US Small Cap Value ETF | Dimensional | 0.00% | $938,489 | — | 2026-11-06 |
| 6 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.02% | $888,405 | $4.3B | 2026-11-06 |
| 7 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.01% | $809,759 | $14.2B | 2026-11-06 |
| 8 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.01% | $645,073 | $11.2B | 2026-11-06 |
| 9 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.00% | $514,910 | — | 2026-09-30 |
| 10 | BSVO EA Bridgeway Omni Small-Cap Value ETF | Nport | 0.02% | $459,048 | — | 2026-06-30 |
| 11 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.02% | $251,221 | $1.2B | 2026-11-06 |
| 12 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.00% | $166,825 | — | 2026-11-06 |
| 13 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.00% | $163,432 | — | 2026-11-06 |
| 14 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.01% | $159,166 | — | 2026-07-31 |
| 15 | EES WisdomTree U.S. SmallCap Fund | Nport | 0.02% | $157,953 | — | 2026-06-30 |
| 16 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.00% | $127,790 | $3.2B | 2026-11-06 |
| 17 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.01% | $81,766 | — | 2026-09-30 |
| 18 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $62,045 | — | 2026-11-06 |
| 19 | RSSL Global X Russell 2000 ETF | Global X | 0.00% | $41,785 | — | 2026-11-09 |
| 20 | TMED T. Rowe Price Health Care ETF | Nport | 0.12% | $28,229 | — | 2026-06-30 |
| 21 | OMFS Invesco Russell 2000 Dynamic Multifactor ETF | Invesco | 0.01% | $16,361 | — | 2026-11-08 |
| 22 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $9,666 | — | 2026-09-30 |
| 23 | IBBQ Invesco Nasdaq Biotechnology ETF | Invesco | 0.01% | $8,061 | — | 2026-11-08 |
| 24 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.00% | $4,896 | — | 2026-11-09 |
| 25 | BIB ProShares Ultra NASDAQ Biotechnology | ProShares | 0.00% | $4,484 | — | 2026-11-09 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.74
TTM Revenue
$0.00
TTM Net Income
$-42.55M
TTM Op. Cash Flow
$-32.84M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-9.90M | $-0.17 | $-7.97M |
| Q1 '26 | 2026-03-31 | — | $-9.04M | $-0.16 | $-10.23M |
| Q4 '25 | 2025-12-31 | $0.00 | $-15.12M | $-0.26 | $-6.79M |
| Q3 '25 | 2025-09-30 | — | $-8.50M | $-0.15 | $-7.85M |
| Q2 '25 | 2025-06-30 | — | $-10.56M | $-0.19 | $-9.16M |
| Q1 '25 | 2025-03-31 | $70.00M | $56.54M | $0.98 | $53.41M |
| Q4 '24 | 2024-12-31 | — | $-15.98M | $-0.28 | $-15.05M |
| Q3 '24 | 2024-09-30 | — | $-15.56M | $-0.28 | $-11.32M |
| Q2 '24 | 2024-06-30 | — | $-19.91M | $-0.36 | $-14.73M |
| Q1 '24 | 2024-03-31 | — | $-18.23M | $-0.35 | $-21.20M |
| Q4 '23 | 2023-12-31 | — | $-19.41M | $-0.34 | $-13.96M |
| Q3 '23 | 2023-09-30 | — | $-23.01M | $-0.45 | $-18.36M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-05
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.97
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-44.3%
ROA
-34.0%
Div Yield
0.00%
FCF Yield
-35.30%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$93.01M
as of 2026-11-11
BDTX vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.26T | 46.0 | +45.5% | +31.2% | 29 |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delawar | $356.3B | 30.1 | +9.7% | +18.7% | 43 |
| GILD Gilead Sciences Inc | $210.0B | — | +6.5% | +39.8% | 46 |
| ISRG Intuitive Surgical Inc. | $159.7B | 54.1 | +20.5% | −20.3% | 17 |
| SYK Stryker Corporation | $124.0B | 34.0 | +7.9% | −8.2% | 36 |
| ALNY Alnylam Pharmaceuticals, Inc. | $21.0B | 7.8 | +56.2% | −61.4% | 57 |
| PODD Insulet Corporation | $10.4B | 27.7 | +29.4% | −47.8% | 25 |
| DYN Dyne Therapeutics, Inc. Common Stock | $3.5B | — | — | −2.2% | 57 |
| BDTX Black Diamond Therapeutics, Inc. Common | $107M | — | — | −34.8% | 100 |
| Peer median | $141.8B | 32.0 | +20.5% | −5.2% | 40 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
5.00M
SI % of Float
11.76%
Days to Cover
7.33
Short Vol Ratio
75.2%
Free Float
42.54M
Float %
74.1%
Short interest 2026-10-15 • Short volume 2026-11-10 • Float 2026-08-07